VincentBabin

Associate

巴黎 + 33.1.56.59.38.35

联系：

Share

Vincent Babin advises innovative companies on how to successfully raise capital, build strong businesses, and pursue external growth transactions. He also assists venture capital investors and corporate venture funds in their investments and in restructuring companies and exits.

When advising founders, Vincent is involved in every stage of a start-up's development, from the constitution of the founding team, to fundraising, external growth M&A, and potential exits. He has valuable experience in setting up employee incentive plans, thinking through the governance of the company, and providing strategic and practical legal advice to clients. Vincent's hands-on experience allows him to advise investors with pragmatism and with a view to creating business value.

Vincent has maintained close ties with the EDHEC Business School, where he occasionally provides training to LL.M. students on venture capital law, as well as legal assistance to the school's entrepreneurs in Station F (a business incubator for start-ups).

Before joining Jones Day in 2023, Vincent worked at other international law firms for several years.

经验

  • Affiliates of Centre Lane Partners acquire substantially all of the assets of Hardinge Inc. and its subsidiaries, including the Kellenberger, USACH, SuperPrecision, and Workholding business linesJones Day advised affiliates of Centre Lane Partners in the acquisition of substantially all of the assets of Hardinge Inc. and its debtor subsidiaries, a global leader and provider of advanced machine tool, manufacturing and workholding solutions, as part of chapter 11 proceedings in the United States Bankruptcy Court for the District of Delaware.
  • Tikehau Capital, Wendel Growth, Definvest (Bpifrance), and 360 Capital sell their stakes in Preligens to SafranJones Day advised Tikehau Capital, Wendel Growth, Definvest (Bpifrance), and 360 Capital in the sale of their stakes in Preligens, a world leader in artificial intelligence (AI) for aerospace and defense, to Safran.
  • Elaia Partners invests in Descartes & MaussJones Day advised Elaia Partners in its participation in the investment of €5.5 million in Descartes & Mauss, a StraTech, a new breed of AI-powered solutions for strategy making.
  • Partech invests in GireveJones Day advised Partech Partners in the €20 million financing of Gireve, the leading digital platform for EV charging interoperability.
  • Daphni and 9900 Capital lead €5 million financing of KoletJones Day advised Daphni and 9900 Capital as lead investors in the €5 million seed financing of Kolet, a French startup specialized in the development and administration of websites and specific software enabling the purchase of dematerialized SIM cards (eSIM), and (ii) the implementation of internet access interfaces and local telecom networks.
  • Silicon Mobility sold to IntelJones Day advised Silicon Mobility SAS in the acquisition of the company by Intel Corporation.
  • Unseenlabs raises €85 millionJones Day advised Unseenlabs, a France-based company and global leader in maritime surveillance through detection and geolocation of radio frequency signals from space, in its €85 million financing for significant expansion of observation capabilities, strengthening of international presence, consolidation of private sector activities, innovation of new products and solutions, and recruitment of new talents.
  • Elaia Partners co-leads €1.7 million financing of PhosphoJones Day advised Elaia Partners as co-lead investor with YCombinator in the €1.7 million pre-seed financing of Phospho for building the next generation of product analytics and monitoring platforms helping developers to create better LLM applications.
  • Elaia Partners participates in €3 million financing of i-VirtualJones Day advised Elaia Partners in connection with the €3 million financing of i-Virtual, the French leader in camera-based vital sign monitoring.
  • Cellectis and AstraZeneca enter into research collaboration and agree on equity investment of up to $220 million by AstraZenecaJones Day advised Cellectis in connection with the joint research collaboration agreement entered into with AstraZeneca and initial equity investment by AstraZeneca into Cellectis of $80 million.
    •

    发送前请注意

    *Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice